In one paragraphArticle in Hypertension (Dallas, Tex. : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Rui TangDivision of General Medicine (R.T., A.E.M., Y.Z.), Columbia University Irving Medical Center, New York, NY.ORCID 0009-0003-8076-9118 Jaejin AnDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena (J.A., K.R.).ORCID 0000-0002-3161-5732 Andrew E MoranDivision of General Medicine (R.T., A.E.M., Y.Z.), Columbia University Irving Medical Center, New York, NY.ORCID 0000-0003-3554-0085 Daichi ShimboDivision of Cardiology (D.S.), Columbia University Irving Medical Center, New York, NY.ORCID 0000-0001-6302-8834 Norrina B AllenDepartments of Preventive Medicine and Medicine (Cardiology), Northwestern University, Chicago, IL (N.B.A.).ORCID 0000-0002-6993-4384 Vanessa XanthakisSection of Preventive Medicine and Epidemiology, Department of Medicine, Boston University, MA (V.X.).ORCID 0000-0002-7352-621X Kristi ReynoldsDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena (J.A., K.R.).ORCID 0000-0001-7619-1649 Yiyi ZhangDivision of General Medicine (R.T., A.E.M., Y.Z.), Columbia University Irving Medical Center, New York, NY.ORCID 0000-0002-8663-5001 Funding
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MWake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3MClinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2MTask Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2MFRAMINGHAM HEART STUDY (FHS), TASK AREA B - PROTOCOL DEVELOPMENT AND BASIC EXAMINATION75N92025D00012 · NHLBI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI LLOYD-JONES, DONALD · 2025 to 2025
$8.9MCORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - COORDINATING CENTER (CC)75N92023D00002 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LI, JING · 2023 to 2025
$6.8MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1MTO EXERCISE OPTION PERIOD ONE (1) FOR TASK AREA A - MESA CORE OPERATIONS, FIELD CENTER.75N92020D00004 · NHLBI · NORTHWESTERN UNIVERSITY · PI SIEGEL, JONATHAN H · 2020 to 2025
$4.5MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00006 · NHLBI · UNIVERSITY OF MINNESOTA · PI PANKOW, JAMES S · 2020 to 2025
$4.4MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00003 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POST, WENDY S · 2020 to 2025
$3.8MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00007 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BERTONI, ALAIN GERALD · 2020 to 2025
$3.5MImproving Blood Pressure Screening and Treatment Strategies in Young AdultsR01HL158790 · NHLBI · KAISER FOUNDATION RESEARCH INSTITUTE · PI AN, JAEJIN, ZHANG, YIYI · 2021 to 2025
$3.5MNCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001420NHLBI NIH HHS 75N92020D00001NHLBI NIH HHS 75N92020D00002NHLBI NIH HHS 75N92020D00003NHLBI NIH HHS 75N92020D00004NHLBI NIH HHS 75N92020D00005NHLBI NIH HHS 75N92020D00006NHLBI NIH HHS 75N92020D00007NHLBI NIH HHS 75N92023D00002NHLBI NIH HHS 75N92023D00003NHLBI NIH HHS 75N92023D00004NHLBI NIH HHS 75N92023D00005NHLBI NIH HHS 75N92023D00006NHLBI NIH HHS 75N92025D00012NHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INHLBI NIH HHS HHSN268201500003CNHLBI NIH HHS HHSN268201500003INHLBI NIH HHS HHSN268201800010INHLBI NIH HHS HHSN268201800011CNHLBI NIH HHS HHSN268201800011INHLBI NIH HHS HHSN268201800012CNHLBI NIH HHS HHSN268201800012INHLBI NIH HHS HHSN268201800014CNHLBI NIH HHS HHSN268201800014INHLBI NIH HHS HHSN268201800015INHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095160NHLBI NIH HHS N01 HC095161NHLBI NIH HHS N01 HC095162NHLBI NIH HHS N01 HC095163NHLBI NIH HHS N01 HC095164NHLBI NIH HHS N01 HC095165NHLBI NIH HHS N01 HC095166NHLBI NIH HHS N01 HC095167NHLBI NIH HHS N01 HC095168NHLBI NIH HHS N01 HC095169NHLBI NIH HHS R01 HL155081NHLBI NIH HHS R01 HL158790NHLBI NIH HHS R01 HL168379NIEHS NIH HHS 75N98025D00022NIEHS NIH HHS 75N98025D00024NIEHS NIH HHS 75N98025D00025NIEHS NIH HHS 75N98025D00026NIEHS NIH HHS 75N98025D00027NIEHS NIH HHS 75N98025D00028NIMHD NIH HHS HHSN268201800013I
6 · The paper itselfAbstract
backgroundWhether isolated diastolic hypertension (IDH) in young adults represents a benign, age-specific phenotype or confers increased cardiovascular disease risk remains uncertain. We assessed the associations between hypertension subtypes, IDH, isolated systolic hypertension, and systolic-diastolic hypertension, with atherosclerotic cardiovascular disease and heart failure. We also characterized longitudinal transitions in hypertension subtypes from young adulthood into later life.
methodsAdults aged ≥18 years without cardiovascular disease were included from 4 US cohorts. Hypertension subtypes were defined using blood pressure thresholds of ≥130/80 mm Hg. Cox proportional hazards models were used to estimate the associations of hypertension subtypes with atherosclerotic cardiovascular disease and heart failure.
resultsAmong 23 957 participants (mean age, 44.5 years, 42.5% were young adults aged 18-39 years, 45.1% were male), 2320 atherosclerotic cardiovascular disease and 1243 heart failure events occurred over a median follow-up of 17.2 years. Among young adults, the adjusted hazard ratios (95% CI) for atherosclerotic cardiovascular disease were 1.36 (95% CI, 1.11-1.68) for IDH, 1.54 (95% CI, 1.02-2.32) for isolated systolic hypertension, and 1.84 (95% CI, 1.46-2.32) for systolic-diastolic hypertension, compared with normotension. Corresponding hazard ratios for heart failure were 1.69 (95% CI, 1.24-2.31) for IDH, 1.92 (95% CI, 1.09-3.40) for isolated systolic hypertension, and 1.69 (95% CI, 1.17-2.43) for systolic-diastolic hypertension. Associations were consistent among adults aged ≥40 years. Among young adults with IDH, 29.8% remained with IDH, whereas 36.5% progressed to systolic-diastolic hypertension later in life.
conclusionsIDH in young adulthood represents an early marker of increased cardiovascular disease risk and a precursor to more adverse hypertension subtypes. These findings underscore the importance of early recognition, ongoing blood pressure monitoring, and guideline-concordant pharmacological treatment, when indicated, among young adults with IDH to reduce long-term cardiovascular disease risk.
Indexed as
Blood PressureCardiovascular DiseasesHeart FailureHypertensionAdolescentAdultBlood Pressure DeterminationDiastoleFemaleHeart Disease Risk FactorsHumansIsolated Systolic HypertensionLongitudinal StudiesMaleProportional Hazards ModelsRisk Assessmentblood pressurecardiovascular diseasesheart failureisolated systolic hypertensionyoung adults
Identifiers
PMID42605677
PMCPMC13483358
What OpenQuestion holds
Textmetadata
Read underepoch 390